Data from a phase II clinical trial reveal impressive responses to rituximab when used in combination with lenalidomide in patients with mucosa-associated lymphoid tissue (MALT) lymphoma. A total of 46 patients, of which 30% had gastric MALT lymphoma, received a maximum of eight courses of rituximab (375 mg/m2 on day 1) plus lenalidomide (20 mg on days 1–20) every 4 weeks. Overall, 80% of patients had a response to treatment, with 54% entering complete remission, compared with 60% in a previous phase II study of lenalidomide monotherapy in patients with MALT lympoma. Investigators reported no unexpected toxicities. The effectiveness of this combination was unaffected by the type of MALT lymphoma (gastric versus extragastric), or whether or not patients had received previous lines of therapy. These data indicate a need for further investigation of the efficacy of this combination in a pilot clinical trial.